Following an April case, fears are amounting over use of generic forms of Reglan. Although Federal law requires generic brands to follow a similar warning label and to report cases of negative reactions, many are concerned that these standards are less enforceable in a wider market.

These fears compound with new healthcare reforms, which will make prescription pharmaceuticals more affordable, and therefore available, for patients. In the April case, the plaintiff’s suit against Wyeth and Schwartz, the corporations responsible for Reglan’s production, failed to provide prior authority that could hold a original manufacturer responsible for similar generic drugs.

With less enforcement from the FDA over generic brands, and a possible explosion in the market, some fear that Reglan poses to endanger a new, greater population in the near future.

If you or someone you love has suffered from averse side-effects due to the prescription drug Reglan, call the Reglan tardive dyskinesia attorneys of Williams Kherkher at 800-781-3955 today.